Hikma Pharmaceuticals plc

Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents

Plus: AbbVie licenses TL1A mAb from FutureGen for IBD, and updates from Takeda, Ascentage, Pfizer, ProFound and more

Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M

Plus AZ’s Sheldon joining GSK (at last) and updates from Sudo, Walden, 1910 and more

NIH updated its COVID-19 treatment guidelines to recommend sotrovimab (VIR-7831) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Vir Biotechnology Inc. (NASDAQ:VIR) to treat high-risk outpatients

An SEC filing released Friday revealed that Josh Bilenker and Jeffrey Engelman have $212 million to begin building newly launched Treeline Biosciences Inc.’s toolbox for chasing validated but

Gilead, HiFiBiO partner on AMLHiFiBiO Therapeutics has closed its second partnership with the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), this time using its antibody and single-cell

Why diagnostic innovation needs Congress to fix patent law’s Section 101